2023-506114-49-00已完成1 期
A study of the safety of the new investigational drug CVN293 in healthy volunteers, and how CVN293 is taken up and processed by the human body.
Cerevance Inc.1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2023年8月15日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 64
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Principal Investigator CHDR
Scientific
Cerevance Inc.
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A study of the safety, absorption and effects of investigational drug ARV-102 in patients with Parkinson's disease.2024-516888-84-00Arvinas Operations Inc.44
招募中
1 期
A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanced cancers2024-515254-24-00Janssen Cilag International74
招募中
1 期
A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)2023-507611-35-00Generate Biomedicines Inc.70
暂停
1 期
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors2023-505322-34-00Beigene Ltd.45
暂停
1 期
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab, in Patients With Advanced or Metastatic Solid Tumors2023-503996-38-00Beigene Ltd.60